Lifeboat Foundation

When Srikanth Singamaneni and Guy Genin, both professors of mechanical engineering and materials science at the McKelvey School of Engineering at Washington University in St. Louis, established a new collaboration with researchers from the School of Medicine in late 2019, they didn’t know the landscape of infectious disease research was about to shift dramatically. In a conference room overlooking Forest Park on a beautiful fall day, the team had one goal in mind: tackle the biggest infectious disease problem facing the world right then.

“Srikanth and I had a vision of a simple, quantitative diagnostic tool, so we connected with infectious disease physicians here at WashU and asked them, ‘What are the most important questions that could be answered if you could get really detailed information cheaply at the point of care?’” said Genin, the Harold and Kathleen Faught Professor of Mechanical Engineering.

“Greg Storch told us that one of the most important challenges facing the field of infectious disease is finding a way to figure out quickly if a patient has a bacterial infection and should get antibiotics or has a viral infection, for which antibiotics will not be effective.”

If your image of nuclear power is giant, cylindrical concrete cooling towers pouring out steam on a site that takes up hundreds of acres of land, soon there will be an alternative: tiny nuclear reactors that produce only one-hundredth the electricity and can even be delivered on a truck.

Small but meaningful amounts of electricity — nearly enough to run a small campus, a hospital or a military complex, for example — will pulse from a new generation of micronuclear reactors. Now, some universities are taking interest.

“What we see is these advanced reactor technologies having a real future in decarbonizing the energy landscape in the U.S. and around the world,” said Caleb Brooks, a nuclear engineering professor at the University of Illinois at Urbana-Champaign.

“We interacted with ChatGPT much like a colleague, asking it to synthesize, simplify and offer counterpoints,” the researchers wrote.

The results from Katcher’s latest study will be written up when Sima dies, but data gathered so far suggests that eight rats that received placebo infusions of saline lived for 34 to 38 months, while eight that received a purified and concentrated form of blood plasma, called E5, lived for 38 to 47 months. They also had improved grip strength. Rats normally live for two to three years, though a contender for the oldest ever is a brown rat that survived on a restricted calorie diet for 4.6 years.

“The real point of our experiments is not so much to extend lifespan, but to extend youthspan, to rejuvenate people, to make their golden years really potentially golden years, instead of years of pain and decrepitude,” Katcher said. “But the fact is, if you manage to do that, you also manage to lengthen life and that’s not a bad side-effect.”

Results from such small studies are tentative at best, but some scientists believe the work, and similar efforts by others, has potential. A preliminary study from a collaboration between Katcher and experts at the University of California in Los Angeles found that infusions of young blood plasma wound back the biological clock on rat liver, blood, heart and a brain region called the hypothalamus. Commenting on the work in 2020, Prof David Sinclair, a leading expert on ageing at Harvard medical school, said if the finding held up, “rejuvenation of the body may become commonplace within our lifetimes”.

EXCLUSIVE: Clones are the next step in extending human life, scientist believes The technique has proved successful in animals but not yet worked in people Dr Alex Zhavoronkov believes it will offer ‘spare’ organs for people as they age Regardless of the huge strides scientists have made towards reaching the elusive goal, immortality remains a pipedream.

Triple-negative breast cancer accounts for approximately 15% of all breast cancer cases. Patients with this subtype typically have poorer outcomes compared to other breast cancers, suggesting the need for improved treatments. One new therapy being investigated at Moffitt Cancer Center involves oncolytic viruses, which infect and kill the cancer cells. In a new article published in Nature Medicine, the researchers, led by Hatem Soliman, M.D., share results from a phase 2 clinical trial of the oncolytic virus talimogene laherparepvec (TVEC) combined with standard chemotherapy in patients with early stage triple-negative breast cancer.

Patients with triple-negative breast cancer lack expression of the estrogen and progesterone receptors and have little to no expression of the protein HER2. As a result, hormone therapy and medicines that target HER2 protein receptors are not effective against this type of cancer. Standard therapy for early stage triple-negative breast cancer has been cytotoxic chemotherapy with the recent addition of pembrolizumab. However, this approach is associated with significant side effects. Many studies have shown that patients who have higher levels of immune cells within their tumors tend to have better responses to therapy. These observations suggest that agents that stimulate the immune system may be beneficial in triple-negative breast cancer.

TVEC is a modified herpes simplex 1 virus that includes coding sequences for the protein GM-CSF, which can stimulate the immune system. It is injected directly into the tumor and undergoes replication within the tumor cells, resulting in the breakdown of the tumor cell and production of tumor derived antigens. Immune cells can recognize the antigens, infiltrate the tumor and target the cancer cells for destruction. In addition, GM-CSF made by the virus acts as a beacon to help recruit immune cells to the tumor.

But the disgraced CRISPR scientist admits his mistakes: “I did it too quickly.”

Scientists have developed a molecular compound that’s so effective in killing off disease-causing fungi that it’s been named after Keanu Reeves. The people of Hollywood may as well pack up and finish awards season early this year, because nothing is going to beat this honour. From The Matrix to John Wick, Keanu Reeves has shown us time and time again how much of a badass he is, and now the science world is ready to recognise him for it.

Innovative treatment designed to treat mitochondrial disease shows promise in a few patients.